Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2026-03-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于提前归还可转债部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the early repayment of part of the funds raised through convertible bonds temporarily used to supplement working capital. It discusses the use and repayment of raised funds, referencing previous announcements and compliance with disclosure obligations. The content focuses on capital management and financing activities rather than financial results, management changes, or regulatory certifications. The key phrases include '募集资金' (raised funds), '可转债' (convertible bonds), '暂时补充流动资金' (temporarily supplement working capital), and '提前归还' (early repayment). This fits the category of Capital/Financing Update (CAP). The document length is short but contains substantive information about financing activities, not just a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2026-03-16 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast (业绩预告) for the fiscal year 2025, providing estimated net profit and earnings growth percentages. It explicitly states that the data is preliminary, unaudited, and that detailed financial data will be disclosed in the 2025 annual report. The document is short (960 characters) and serves as an announcement of expected financial results rather than a full financial report. It does not contain actual financial statements or detailed analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is also not a certification or regulatory attestation. Therefore, this document fits best as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only.
2026-01-22 Chinese
关于提前归还可转债部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the early repayment of part of the funds raised through convertible bonds temporarily used to supplement working capital. It discusses the use and repayment of raised funds, referencing previous announcements and providing updates on the status of these funds. There is no detailed financial report or comprehensive financial statements included. The document is short (894 characters) and serves as a formal update on capital usage and repayment. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2026-01-06 Chinese
东莞证券股份有限公司关于特一药业集团股份有限公司公开发行可转换公司债券募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the delay in investment projects funded by the proceeds from a convertible bond issuance by Te Yi Pharmaceutical Group Co., Ltd. It includes specifics about the bond issuance, the use of funds, project investment details, reasons for project delays, and the board's approval of the delay. The document is focused on the status and regulatory compliance of the use of raised funds and the postponement of investment projects. It is not a full annual or interim financial report, nor is it an earnings release or a call transcript. It is not a simple announcement or a certification letter but a formal verification opinion related to capital raising and investment project progress. This fits best under the category of Capital/Financing Update (CAP), as it deals with updates on the use of funds raised through convertible bonds and related project progress and delays.
2025-12-23 Chinese
关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 特一药业集团股份有限公司 regarding the delay of certain fundraising investment projects. It details the use of funds raised through convertible bonds, the progress and delay of specific projects, and the board's approval of the delay. The document includes financial figures related to the fundraising and investment projects but does not contain comprehensive financial statements or detailed financial performance analysis. It is primarily an update on capital use and project timelines related to fundraising activities. The document length is 3570 characters, which is relatively short and focused on a specific capital/financing update rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-12-23 Chinese
关于第六届董事会第五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the fifth meeting of the sixth board of directors of the company. It includes details about the meeting date, attendance, and voting results on a specific agenda item. It does not contain financial statements or detailed management discussion but rather reports on board decisions. This fits the category of Board/Management Information (MANG). The document length is short and focused on board meeting resolutions, not a full report or announcement of voting results at a shareholder meeting, so it is not DVA. Therefore, the classification is MANG with high confidence.
2025-12-23 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.